Clinical Study Of Neoadjuvant Chemotherapy With TE And TC Regimens In Elderly Patients With Breast Cancer

Objective:To investigate the difference of the two groups of efficacy and toxic responses of elderly patients with breast cancer by neoadjuvant chemotherapy with TE(docetaxelplus epirubicin)and TC(docetaxelpluscyclophosphamide)regimen,in order to provide clinical evidence for the selection of optimal regimen.Methods: Collecting 60 patientswho met the inclusion criteria,divided randomly into two groups.The two groups received neoadjuvant chemotherapy with TE or TC regimen respectively,repeated every 3 weeks.Andre-examinationafter per2 cycles of chemotherapy.Recent curative effect,R0 resection ratesand toxic responses was compared after two groups underwent neoadjuvant chemotherapy.Then the data wereanalysed statistically.Results: The response rate(CR+PR)of TE group and TC group were 81.25%and 75%,respectively,there was no significant difference(P > 0.05).Most of the patients were treated with surgery after neoadjuvant chemotherapy.There was no significant difference in surgical treatment between TE group andTC group(P >0.05).And patients in TE group underwent surgical treatment(R0 resection)was 27 cases,TC group was 20 cases,the R0 resection rates were 84.38% and71.43%.Comparison between TE and TC group,the incidence of cardiotoxicity was28.12%(9/32)and 14.29%(4/28),there was no significant difference(P > 0.05).The same as anemia(P > 0.05).But in gastrointestinal reaction,dental ulcer and neutropenia,thedifference was statistically significant(P<0.05).And the differences in adverse reactionswith above grade Ⅲ were mainly reflected in gastrointestinal reactions(P<0.05).Conclusion:The efficacy of TC regimen is similar to that of TE regimen,but the TC regimen is more tolerable than the TE regimen in the treatment of elderly breast cancer patients,and it is worthy of clinical promotion.